Concepedia

Cutaneous toxicities associated with epidermal growth factor receptor and mesenchymal epithelial transition factor dual blockade via bispecific antibody amivantamab

Isabel Arana, Grant J. Riew, Adam Rock, Vinod E. Nambudiri, Badri Modi, Connie R. Shi

Journal of the American Academy of Dermatology · 2025 · 10 citations · 4 references

Concepts

MedicineOncologyPharmacologyChemotherapyCutaneous OncologyImmunotherapyBispecific AntibodiesBispecific Antibody TherapyDermatologic Toxicity ManagementGrowth Factor SignalingTargeted Cancer TherapyTargeted TherapyAntibody-drug Conjugate BispecificsBispecific Antibody CombinationsBispecific Antibody ConjugatesBispecific Antibody DiscoveryEpidermal Growth Factor Receptor InhibitionEpidermal Growth Factor Receptor SignalingEpidermal Growth Factor Receptor Targeting Ligands

References

4

Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

Keunchil Park, Eric B. Haura, Natasha B. Leighl et al. · Journal of Clinical Oncology · 2021 · 632 citations · Full text

Medicine, Oncology, Pharmacology +17

Amivantamab plus Chemotherapy in NSCLC with <i>EGFR</i> Exon 20 Insertions

Caicun Zhou, Kejing Tang, Byoung Chul Cho et al. · New England Journal of Medicine · 2023 · 347 citations

Medicine, Oncology, Pharmacology +14

Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC

Kaiwen Wang, Robyn Du, Nathaniel J. Myall et al. · Journal of Thoracic Oncology · 2023 · 25 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Spectrum of Dermatologic Adverse Events Associated With Amivantamab Use

Annika Belzer, Michael O. Nguyen, Ashita D. Talsania et al. · JAMA Dermatology · 2022 · 13 citations · Full text

Pharmacy, Dermatology, Pharmacotherapy +15